How to identify stroke mimics in patients eligible for intravenous thrombolysis?

被引:80
作者
Foerster, A. [1 ]
Griebe, M. [1 ]
Wolf, M. E. [1 ]
Szabo, K. [1 ]
Hennerici, M. G. [1 ]
Kern, R. [1 ]
机构
[1] Heidelberg Univ, Dept Neurol, Univ Med Mannheim, D-68137 Mannheim, Germany
关键词
Stroke; Stroke mimics; rtPA; Thrombolysis; TISSUE-PLASMINOGEN ACTIVATOR; ISCHEMIC-STROKE; DOUBLE-BLIND; ALTEPLASE; SAFETY; GUIDELINES; OUTCOMES; TRIAL;
D O I
10.1007/s00415-011-6354-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Since decision-making for thrombolysis in acute stroke settings is restricted to a limited time window and based on clinical assessment and CT findings only, thrombolysis is sometimes applied to patients with a final diagnosis other than a stroke. From a prospectively collected stroke/MRI data bank (2004-2010) with 648 suspected ischemic stroke patients treated with rtPA, we identified patients without evidence of acute infarction on follow-up MRI and a final diagnosis other than a stroke or acute cerebrovascular event. We compared demographics, symptoms, complications, and outcome of patients with stroke mimics (SM) to those with acute infarction. In 42 patients, an SM was diagnosed: seizures in 20, conversion disorder in seven, dementia in six, migraine in three, brain tumor in two, and others in four patients. Patients with SM less often had typical stroke symptoms like dysarthria (p < 0.01), facial palsy (p < 0.001), hemiparesis (p < 0.001), horizontal gaze palsy (p < 0.001), and visuospatial neglect (p = 0.03), while aphasia (p = 0.004) and accompanying convulsions (p = 0.01) occurred more often. Independent predictors of SM were known cognitive impairment, aphasia, and accompanying convulsions. Thrombolysis-related complications (orolingual angioedema) occurred in one SM patient and none of the SM patients deteriorated clinically. Stroke mimics comprise neurological/psychiatric disorders and differ from ischemic stroke patients with regard to the clinical presentation at onset. This might be helpful in deciding which patients should undergo acute stroke MRI to rule out SM, facilitate treatment decisions, and reduce the risk of unnecessary therapy.
引用
收藏
页码:1347 / 1353
页数:7
相关论文
共 20 条
[1]   Guidelines for the early management of adults with ischemic stroke - A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups [J].
Adams, Harold P., Jr. ;
del Zoppo, Gregory ;
Alberts, Mark J. ;
Bhatt, Deepak L. ;
Brass, Lawrence ;
Furlan, Anthony ;
Grubb, Robert L. ;
Higashida, Randall T. ;
Jauch, Edward C. ;
Kidwell, Chelsea ;
Lyden, Patrick D. ;
Morgenstern, Lewis B. ;
Qureshi, Adnan I. ;
Rosenwasser, Robert H. ;
Scott, Phillip A. ;
Wijdicks, Eelco F. M. .
STROKE, 2007, 38 (05) :1655-1711
[2]   From the stroke unit to the stroke competence center: corresponding beneficial clinical and financial effects [J].
Chatzikonstantinou, A. ;
Foerster, A. ;
Hennerici, M. G. ;
Baezner, H. .
JOURNAL OF NEUROLOGY, 2011, 258 (11) :1929-1932
[3]   Intravenous thrombolytic therapy in patients with stroke mimics: baseline characteristics and safety profile [J].
Chen, Y. ;
Bogosavljevic, V. ;
Leys, D. ;
Jovanovic, D. ;
Beslac-Bumbasirevic, L. ;
Lucas, C. .
EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 (10) :1246-1250
[4]   Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia [J].
Chernyshev, O. Y. ;
Martin-Schild, S. ;
Albright, K. C. ;
Barreto, A. ;
Misra, V. ;
Acosta, I. ;
Grotta, J. C. ;
Savitz, S. I. .
NEUROLOGY, 2010, 74 (17) :1340-1345
[5]   Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial [J].
Clark, WM ;
Wissman, S ;
Albers, GW ;
Jhamandas, JH ;
Madden, KP ;
Hamilton, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2019-2026
[6]   The rtPA (Alteplase) 0-to 6-hour acute stroke trial, part A (A0276g) - Results of a double-blind, placebo-controlled, multicenter study [J].
Clark, WM ;
Albers, GW ;
Madden, KP ;
Hamilton, S .
STROKE, 2000, 31 (04) :811-816
[7]   Intravenous alteplase for stroke - Beyond the guidelines and in particular clinical situations [J].
De Keyser, Jacques ;
Gdovinova, Zuzana ;
Uyttenboogaart, Maarten ;
Vroomen, Patrick C. ;
Luijckx, Gert Jan .
STROKE, 2007, 38 (09) :2612-2618
[8]   Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].
Hacke, W ;
Kaste, M ;
Fieschi, C ;
von Kummer, R ;
Davalos, A ;
Meier, D ;
Larrue, V ;
Bluhmki, E ;
Davis, S ;
Donnan, G ;
Schneider, D ;
Diez-Tejedor, E ;
Trouillas, P .
LANCET, 1998, 352 (9136) :1245-1251
[9]  
HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
[10]   Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke [J].
Hacke, Werner ;
Kaste, Markku ;
Bluhmki, Erich ;
Brozman, Miroslav ;
Davalos, Antoni ;
Guidetti, Donata ;
Larrue, Vincent ;
Lees, Kennedy R. ;
Medeghri, Zakaria ;
Machnig, Thomas ;
Schneider, Dietmar ;
von Kummer, Ruediger ;
Wahlgren, Nils ;
Toni, Danilo .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (13) :1317-1329